Skip to main content

Table 9 Effect of FVBM, F18 bioactive compound and atorvastatin on in vivo modulation of hepatic HMG-CoA reductase activity in Triton WR-1339 induced hyperlipidemic rats after 18 hours of the treatment

From: Bioactivity guided fractionation and hypolipidemic property of a novel HMG-CoA reductase inhibitor from Ficus virens Ait

Group HMG-CoA reductase activity
NC 4.35 ± 0.22*
HLC 1.21 ± 0.041*
(+3.59 f)a
FVT-1 2.499 ± 0.057*
(−2.06 f)a
FVT-2 4.24 ± 0.15*
(−3.50 f)a
CT 3.85 ± 0.13*
  (−3.18 f)a
AT 2.64 ± 0.075*
(−2.18 f)a
  1. Expressed as ratio of HMG-CoA to Mevelonate; lower the ratio higher the enzyme activity.
  2. *Values are mean ± SD from liver homogenate of 5 rats in each group.
  3. NC, normal control; HLC, triton induced hyperlipidemic control; FVT-1, fed 50 mg FVBM extract/rat; FVT-2, fed 100 mg FVBM extract/rat; CT, fed 1 mg F18 bioactive compound/rat and AT, given 1 mg atorvastatin/rat for once.
  4. Significantly different from NC at ap < 0.001.
  5. Significantly different from HLC at ap < 0.001.